NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Tuesday that its first-quarter revenues ramped up 3 percent year over year, as the company fell short of consensus analyst estimates on the top and bottom lines.

The Hercules, Calif.-based firm said that revenues for the three months ended March 31 totaled $499.7 million, up from $486.3 million a year ago, but below the average Wall Street estimate of $506.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.